AG真人官方

Charles Schwab Corporation (SCHW) 鈥� Form 4 insider filing

On 07/01/2025, independent director Charles A. Ruffel received a non-qualified stock option for 1,322 shares of Charles Schwab common stock at an exercise price of $91.17. The option was granted under the company鈥檚 Directors鈥� Deferred Compensation Plan II, vests immediately, and expires on 07/01/2035. The award was taken in lieu of cash director fees, indicating the director鈥檚 choice to align compensation with future share performance. Following the grant, Mr. Ruffel beneficially owns 1,322 derivative securities (options) directly; no changes were reported in his non-derivative (common-stock) holdings.

The transaction is routine board compensation and does not involve open-market purchases or sales. While it marginally increases insider exposure to the stock, the small size (鈮�$120k notional value at grant price) suggests limited market impact.

Microchip Technology Inc. (MCHP) 鈥� Form 4 filing (07/03/2025)

Senior Vice-President of Operations Mathew B. Bunker reported routine equity awards dated July 1, 2025. No shares were sold; all transactions were grants that increase the executive鈥檚 potential ownership:

• Performance Stock Units (PSUs): 2,093 target shares vesting 08/15/2029 and 62 target shares vesting 08/15/2028. Payout is contingent on Microchip achieving a 29 % cumulative non-GAAP operating margin over 12 quarters ending 06/30/2028; actual shares can be higher or lower than target.
• Restricted Stock Units (RSUs): 2,092 shares vesting 08/15/2029 and 62 shares vesting 08/15/2028.
• Post-transaction, Bunker directly owns 27,732 common shares; the newly granted 4,309 derivative units (PSUs + RSUs) are in addition to that holding.

The filing reflects standard incentive compensation under the company鈥檚 2004 Equity Incentive Plan. Because there is no open-market purchase or sale and the share count involved is immaterial relative to Microchip鈥檚 ~550 million shares outstanding, the event is neutral for shareholders and largely administrative.

Form 4 filing for The Charles Schwab Corporation (SCHW) discloses that director Stephen A. Ellis acquired 371 restricted stock units (RSUs) on 07/01/2025 under the company鈥檚 Directors鈥� Deferred Compensation Plan II. The RSUs, received in lieu of cash board fees, are held in a rabbi trust and will be distributed when the director leaves the Board. Following the transaction, Ellis now beneficially owns 11,626.64 RSUs, including 34.77 units accumulated through dividend reinvestment. No shares were sold, and the filing reflects routine equity-based compensation rather than an open-market purchase.

The Charles Schwab Corporation (SCHW) 鈥� Form 4 Insider Filing

On 1 July 2025, director Marianne C. Brown reported the acquisition of 412 restricted stock units (RSUs) under the company鈥檚 Directors鈥� Deferred Compensation Plan II. The equity was taken in lieu of cash board fees and is held in a rabbi trust until she leaves the Board of Directors. After the grant, Brown鈥檚 direct beneficial ownership rose to 6,525.39 RSUs, a figure that includes 18.88 units gained through dividend reinvestment. No shares were sold or disposed of, and no option exercises occurred. Because the transaction represents routine, non-cash director compensation rather than an open-market purchase or sale, it is considered to have minimal immediate market impact but modestly strengthens director鈥搒hareholder alignment.

On July 3, 2025, a Form 144 filing disclosed that insider Carolyn S. Pomerantz plans to sell up to 72,000 common shares of The Charles Schwab Corporation (SCHW) through Charles Schwab Corp. as broker. The shares have an estimated aggregate market value of $6.58 million. The filing states the shares originated from a February 14, 2022 gift.

The document also lists recent activity: over the past three months Pomerantz sold an additional 72,907 shares for total gross proceeds of $6.17 million. After the proposed sale, her disclosed sales in 2025 would reach roughly 144,907 shares. Given Schwab鈥檚 1.82 billion shares outstanding, the new sale represents about 0.004 % of the float, suggesting limited direct dilution or price impact.

Form 144 serves only as advance notice; execution is not guaranteed. No 10b5-1 plan adoption date was provided, and the filer certified she possesses no undisclosed adverse information. Investors may view continued insider selling as a sentiment datapoint, but the scale appears immaterial to Schwab鈥檚 capital structure.

Inhibikase Therapeutics, Inc. (IKT) has filed an amended Form 4 (Form 4/A) for Chief Executive Officer and Director Mark T. Iwicki. The sole purpose of the amendment is to correct two data points that were misstated in the original Form 4 filed on 25 Feb 2025: (i) the exercise price of a stock-option award and (ii) its expiration date.

Key terms of the option grant (originally awarded 21 Feb 2025):

• Derivative security: Non-qualified stock option to purchase 602,346 shares of common stock.
• Corrected exercise price: $2.97 per share.
• Corrected expiration date: 21 Feb 2035 (10-year term).
• Vesting schedule: 48 substantially equal monthly installments beginning 21 Mar 2025, contingent on continued employment.
• Ownership status: Shares are held directly by the reporting person.

The filing does not report new purchases or sales of shares; it is an administrative correction. Nevertheless, the option grant, if fully exercised, would result in issuance of up to 602,346 new shares, creating a modest potential dilution for existing shareholders. Because the option vests over four years, dilution would be gradual and contingent on share-price appreciation above $2.97.

Investor takeaways: (1) Management has rectified an earlier clerical error, demonstrating regulatory compliance; (2) the CEO鈥檚 long-term incentive package now has confirmed terms, aligning his interests with shareholders; (3) no immediate cash outflow or revenue impact is associated with the amendment.

Form 4 Overview: Director Anna Massion has reported the automatic disposition of her equity interests in PlayAGS, Inc. ("AGS") that occurred upon the closing of the Brightstar-backed merger on 30 June 2025.

• Securities disposed: 66,003 common shares and 6,544 restricted stock units (RSUs).
• Cash consideration: Each share and RSU equivalent was converted into the right to receive $12.50 in cash, without interest, subject to applicable withholding taxes.
• Mechanism: At the merger鈥檚 effective time, all AGS shares were cancelled and ceased to exist; the RSUs were similarly cancelled in exchange for cash.
• Post-transaction ownership: The reporting person now holds zero AGS equity; ownership had been classified as 鈥淒irect.鈥�

The filing confirms consummation of the Agreement and Plan of Merger dated 8 May 2024 among PlayAGS, Bingo Holdings I, LLC (an affiliate of Brightstar Capital Partners), and Bingo Merger Sub, Inc. The transaction effectively transitions PlayAGS from a public to a private company.

No derivative securities remain, and no additional trades or price variations beyond the fixed $12.50 cash-out value are disclosed.

Director Stephen A. Ellis of Charles Schwab executed notable insider transactions on June 24, 2025:

• Exercised 1,853 nonqualified stock options at a strike price of $33.12 per share
• Acquired 1,853 shares of common stock through option exercise
• Contributed the newly acquired shares plus additional 2,379 shares to a revocable trust

Following these transactions, Ellis's holdings include:

• 6,660 shares held directly
• 93,389 shares held indirectly through trust (including 304 shares from dividend reinvestment)

The stock options were granted under the Directors' Deferred Compensation Plan II with immediate vesting and were set to expire on July 1, 2025. This Form 4 filing was submitted by attorney-in-fact P. Blake Allen on June 26, 2025.

Charles Schwab Chief Risk Officer Nigel J. Murtagh reported significant insider trading activity on June 18, 2025. The transactions involved:

• Exercise of 20,872 nonqualified stock options at a strike price of $42.99
• Immediate sale of all exercised shares at an average price of $90.0089 per share
• The sale was executed under a pre-established Rule 10b5-1 trading plan from November 23, 2024

Following these transactions, Murtagh's holdings include 58,999 shares held directly and 2,374 shares held indirectly through an ESPP. The exercised options were granted under the 2013 Stock Incentive Plan and had completely vested in four annual installments. The options were set to expire on March 1, 2027, but were exercised well before expiration.